Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 38

May 23, 2024 00:35:24
Episode Cover

Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...

Listen

Episode 27

January 12, 2023 00:33:36
Episode Cover

Episode 27, Part 1: Jamie Heywood, Biotech Engineer and Entrepreneur

"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of...

Listen

Episode 36

December 05, 2023 00:51:43
Episode Cover

Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...

Listen